Printer Friendly

ATP ACQUIRES WORLDWIDE RIGHTS TO NEW NICOTINE INHALER TECHNOLOGY

 ATP ACQUIRES WORLDWIDE RIGHTS TO NEW NICOTINE INHALER TECHNOLOGY
 SAN ANTONIO, Texas, Oct. 29 /PRNewswire/ -- San Antonio-based Advanced Therapeutic Products (NASDAQ: ATPI), today announced the licensing of the exclusive worldwide rights to dry aerosol nicotine inhaler technology for use in smoking cessation that was developed at Duke University by Dr. Jed E. Rose, co-developer of the Habitrol(R) nicotine patch.
 ATP President and Chief Executive Officer Jim Linehan made the announcements and also said the company had signed an agreement for a fee payable to ATP with Kabi-Pharmacia Therapeutics AB, a worldwide pharmaceutical company based in Sweden that markets Nicorette chewing gum, the Nicotrol nicotine patch, and owns nicotine vaporizer technology purchased from ATP in 1987, to evaluate the dry aerosol inhaler technology through Dec. 31, 1992.
 "We're excited to be a part of this joint developmental relationship with a scientist the caliber of Dr. Rose, who has been a pioneer in the field of nicotine research for many years and has an impressive record of transferring technology into commercial applications," Linehan said. "To us, the significance of having the exclusive worldwide rights lies in the enormous potential of this new nicotine technology for use in many types of therapeutic and medical applications, in addition to its use as a smoking cessation product."
 Although details of the new dry aerosol nicotine inhaler are still proprietary, Linehan noted that this new technology is in the embryonic stage of development and will require several years of development and study prior to being introduced as a commercial product.
 Linehan added that the first product to break into what today has become a multimillion-dollar market for smoking cessation products and gain worldwide attention was Nicorette chewing gum, which was first introduced in the United States by Kabi-Pharmacia in the early 1980s and had no competition as recently as a year ago. Today, four major pharmaceutical companies -- Kabi-Pharmacia (marketed in the United States by the Parke Davis Division of Warner Lambert), Ciba Geigy, Marion Merrill Dow and Lederle Laboratories -- are marketing nicotine patches, which have become the top-selling smoking cessation products in the United States.
 The nicotine vaporizer, a potential third-generation product, has been in clinical trials since 1990 and is scheduled for a new drug application to the Federal Drug Administration in the fall of 1993. In 1992 ATP received advanced royalty payments from Kabi-Pharmacia AB of $400,000.
 Advanced Therapeutic Products also announced revenues of $404,600 and net income of $230,275 for the fiscal year ending June 30, 1992, as compared to $604,500 in revenues and $200,579 in net income the previous year.
 Earnings for the current year were 2.9 cents per share compared to 2.5 cents per share for the previous year. The company had approximately 7,900,000 shares of common stock outstanding at year's end and total equity of approximately $1,250,000. The ATP common stock is listed on the NASDAQ Electronic Bulletin Board under the symbol "ATPI."
 -0- 10/29/92
 /CONTACT: Jim Linehan of Advanced Therapeutic Products, 512-490-2292, or Cary Corbin, Dublin-McCarter & Associates, 512-227-0221/
 (ATPI) CO: Advanced Therapeutic Products ST: Texas IN: MTC SU: TNM


MA -- NY051 -- 6574 10/29/92 12:23 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 29, 1992
Words:533
Previous Article:XOMA ANNOUNCES NEW STRATEGIC FOCUS AND RESTRUCTURING
Next Article:NEW JERSEY RESOURCES CORPORATION ANNOUNCES IMPROVED FISCAL 1992 FINANCIAL RESULTS
Topics:


Related Articles
Nicotine Inhaler Launched in Sweden
Nicotine Inhaler Launched in Austria
ATP Announces U.S. Introduction of Nicotine Inhaler
ATP Announces Nicotine Inhaler's Baltimore Launch
ATP Announces Nicotine Inhaler's Nationwide Launch
ATP Profits Continue to Increase.
ATP Announces Profits.
ATP Announces Profits.
ATP Earnings Increase.
ATP Revises Agreements With Pharmacia & Upjohn.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters